Tag
The PARTHENOPE randomized trial demonstrates that personalizing DAPT duration (3 to 24 months) based on individual risk scores significantly reduces net adverse clinical events compared to standard 12-month therapy, primarily by lowering is
In a randomized trial of 316 patients with ischemic stroke/TIA, nonvalvular atrial fibrillation, and atherosclerotic disease, adding an antiplatelet to anticoagulation did not reduce ischemic events but doubled clinically relevant bleeding
This post hoc AFIRE trial analysis shows rivaroxaban monotherapy reduces major cardiovascular events and major bleeding across age groups in AF with stable CAD, with notable age-related efficacy and safety trends warranting further research
